Nyxoah Sa's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2025 to a ratio of 1.51, above the company average. This is a clear sign of healthy business climate in the Medical Equipment & Supplies industry and improving liquidity at their respective customers, during the fourth quarter 2025. Average receivable collection period, for the Nyxoah Sa in Dec 31 2025 quarter, has decreased to 242 days, compared to 500 days, in the 0 quarter.

If we take a look into Healthcare sector 571 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2025 from 0 to 3855.

What is Receivable Turnover Ratio?
What is Nyxoah Sa Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NYXH Receivables Turnover Ratio	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Receivable Change	21.23 %	21.23 %	21.23 %	21.23 %	125.99 %
Y / Y Revenue Change	156.29 %	-	82.96 %	-	258.85 %
Receivable Turnover Ratio (TTM)	1.51	0.73	0.77	0.71	0.75
NYXH's Total Ranking	# 3855	# 0	#	#	#
Accounts Receivable average collection period days	242	499	476	514	488
Seq. Receivable Change	0 %	0 %	0 %	21.23 %	0 %
Seq. Revenue Change	-	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 188
Healthcare Sector	# 572
Overall Market	# 3855

Receivable Turnover Ratio Statistics
High	Average	Low
0.8	0.8	0.8
(Dec 31 2025)

NYXH Company Profile • Back to NYXH Efficiency Comparisons • Compare NYXH Receivables Turnover Ratio to its Competitors

Financial Statements
Nyxoah Sa's Accounts Receivable	$ 8 Millions	Visit NYXH's Balance sheet
Nyxoah Sa's Sales TTM	$ 13 Millions	Visit NYXH's Income Statement
Sources of NYXH's Revenues		Visit NYXH's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Equipment & Supplies Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NYXH's Receivable Turnover Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NYXH's Growth Rates	NYXH's Roa	NYXH's Inventory Turnover Ratio	NYXH's Dividend Comparisons
NYXH's Profitability Ratios	NYXH's Roi	NYXH's Asset Turnover Ratio	NYXH's Dividend Growth
NYXH's Valuation Ratios	NYXH's Roe	NYXH's Financial Strength Ratios	NYXH's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Dec 31 2025	Receivable at quarter ending Dec 31 2025
Dyadic International Inc	4.10	$ 3.090 Millions	$ 0.753 Millions
Elite Pharmaceuticals Inc	4.09	$ 138.547 Millions	$ 33.876 Millions
Butterfly Network Inc	4.05	$ 96.734 Millions	$ 23.893 Millions
Ironwood Pharmaceuticals inc	4.04	$ 296.151 Millions	$ 73.264 Millions
Adma Biologics Inc	4.02	$ 508.113 Millions	$ 126.310 Millions
Upstream Bio Inc	4.00	$ 2.854 Millions	$ 0.714 Millions
Immunitybio inc	3.98	$ 113.288 Millions	$ 28.435 Millions
Apyx Medical Corp	3.95	$ 52.044 Millions	$ 13.166 Millions
Kymera Therapeutics Inc	3.92	$ 39.211 Millions	$ 10.000 Millions
Stevanato Group S p a	3.92	$ 1,328.636 Millions	$ 339.011 Millions
Biomarin Pharmaceutical Inc	3.91	$ 3,221.253 Millions	$ 823.378 Millions
Teva Pharmaceutical Industries Limited	3.88	$ 14,047.000 Millions	$ 3,616.750 Millions
Astrazeneca Plc	3.87	$ 58,739.000 Millions	$ 15,177.000 Millions
Dexcom Inc	3.86	$ 4,661.900 Millions	$ 1,207.425 Millions
Akebia Therapeutics Inc	3.82	$ 236.196 Millions	$ 61.900 Millions
Omniab Inc	3.80	$ 18.666 Millions	$ 4.917 Millions
Lifeward ltd	3.78	$ 22.034 Millions	$ 5.823 Millions
Iovance Biotherapeutics inc	3.76	$ 263.502 Millions	$ 70.021 Millions
Cyclerion Therapeutics Inc	3.76	$ 2.074 Millions	$ 0.552 Millions
Procept Biorobotics Corporation	3.75	$ 307.226 Millions	$ 82.030 Millions
Lightwave Logic Inc	3.70	$ 0.237 Millions	$ 0.064 Millions
Organogenesis Holdings Inc	3.70	$ 564.169 Millions	$ 152.484 Millions
Cumberland Pharmaceuticals Inc	3.70	$ 44.521 Millions	$ 12.045 Millions
Apollomics Inc	3.69	$ 8.500 Millions	$ 2.305 Millions
Align Technology inc	3.68	$ 4,034.013 Millions	$ 1,094.829 Millions
Xencor Inc	3.68	$ 125.576 Millions	$ 34.111 Millions
Lexicon Pharmaceuticals Inc	3.67	$ 49.803 Millions	$ 13.587 Millions
Absci Corp	3.63	$ 2.800 Millions	$ 0.771 Millions
Redhill Biopharma Ltd	3.62	$ 0.286 Millions	$ 0.079 Millions
Ani Pharmaceuticals Inc	3.61	$ 883.366 Millions	$ 244.922 Millions

Date modified: 2026-07-07T12:29:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.